Nociscan is designed to locate the source of chronic lower back pain.
In a corporate update, the company shared key milestones including multiple partnerships with spine surgeon leaders in the U.S., significant payer coverage in the U.K. and having more than $50 million invested into the platform.
Nociscan’s technology is also protected by 23 U.S. patents, 17 international patents, and there are 12 pending patent applications.
“We are excited with the recent positive success we have been awarded as Aclarion has consistently achieved stated catalysts of value creation that fall into a very concise framework proven to bring disruptive technological advancements to standard of care in the healthcare sector,” Brent Ness, Aclarion CEO, said in the release.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
